Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging. Journal Abstract - Guideline Central

Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging.

Published: 2026

Authors

, , , , , , , , , , , ,

Abstract

Lecanemab provides clinical benefits in early Alzheimer's disease (AD), but its longitudinal effects on brain structure, particularly cerebrospinal fluid (CSF) compartments, remain unclear. This study examined treatment-associated structural changes using longitudinal MRI.

Keywords: Alzheimer's disease, CSF dynamics, lecanemab, longitudinal imaging, structural MRI

Source

Alzheimer's & dementia (Amsterdam, Netherlands)

Publication Type

Journal Article

Language

English

PubMed ID

42255966

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.